论文部分内容阅读
目的探讨奥氮平治疗恶性肿瘤相关性抑郁和焦虑状态患者的疗效及安全性。方法选取2012年1月至2015年1月间江门市人民医院收治的105例恶性肿瘤伴相关性抑郁和焦虑患者,采用随机数字表法分为观察组(54例)和对照组(51例)。观察组患者给予奥氮平(10mg/d,连用4周)治疗,对照组患者采用安慰、鼓励、帮助、同情及换位思考等心理支持治疗。采用汉密尔顿抑郁量表(HAMD-24)和汉密尔顿焦虑量表(HAMA-14)于治疗前和治疗后第2、4周末分别评定疗效。结果两组患者治疗后HAMD和HAMA评分均较治疗前下降,且观察组患者治疗后HAMD和HAMA评分均比对照组患者下降显著,差异均有统计学意义(均P<0.05)。观察组患者治疗后HAMD和HAMA治疗总有效率均高于对照组患者,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率均轻微,差异无统计学意义(P>0.05)。结论奥氮平能够有效改善肿瘤患者相关性焦虑和抑郁,临床应用方便,不良反应轻,患者可耐受。
Objective To investigate the efficacy and safety of olanzapine in the treatment of patients with depression and anxiety related to malignant tumors. Methods 105 patients with malignant tumor associated with depression and anxiety who were admitted to Jiangmen Municipal People’s Hospital from January 2012 to January 2015 were randomly divided into observation group (n = 54) and control group (n = 51) . Patients in the observation group were treated with olanzapine (10 mg / d for 4 weeks), and patients in the control group were treated with psychological support such as comfort, encouragement, help, empathy and empathy. The effects of HAMD-24 and HAMA-14 were evaluated before treatment and at the end of the second and fourth week after treatment respectively. Results The HAMD and HAMA scores of both groups decreased after treatment, and the scores of HAMD and HAMA in the observation group were significantly lower than those in the control group after treatment (all P <0.05). The total effective rate of HAMD and HAMA in the observation group was higher than that in the control group after treatment (all P <0.05). Adverse reactions in both groups were mild, the difference was not statistically significant (P> 0.05). Conclusion Olanzapine can effectively improve the related anxiety and depression in patients with cancer. The clinical application is convenient, the adverse reactions are mild and the patients can tolerate.